Journal of Addiction Medicine

Article	Citations
The Relationship Between Children's Problematic Internet-related Behaviors and Psychological Distress During the Onset of the COVID-19 Pandemic: A Longitudinal Study	61
Evidence of Buprenorphine-precipitated Withdrawal in Persons Who Use Fentanyl	60
Cannabis Use During the COVID-19 Pandemic in Canada: A Repeated Cross-sectional Study	48
Management of Xylazine Withdrawal in a Hospitalized Patient: A Case Report	45
A Telemedicine Buprenorphine Clinic to Serve New York City: Initial Evaluation of the NYC Public Hospital System's Initiative to Expand Treatment Access During the COVID-19 Pandemic	39
Impacts of the COVID-19 Shutdown on Gambling Patterns in Australia: Consideration of Problem Gambling and Psychological Distress	36
Low-dose Buprenorphine Initiation in Hospitalized Adults With Opioid Use Disorder: A Retrospective Cohort Analysis	36
Peer Recovery Support Services Across the Continuum: In Community, Hospital, Corrections, and Treatment and Recovery Agency Settings – A Narrative Review	35
The Impacts of COVID-19 on Mental Health, Substance Use, and Overdose Concerns of People Who Use Drugs in Rural Communities	35
Low Dose Initiation of Buprenorphine: A Narrative Review and Practical Approach	32
Adapting a Low-threshold Buprenorphine Program for Vulnerable Populations During the COVID-19 Pandemic	30
Trust in Hospital Physicians Among Patients With Substance Use Disorder Referred to an Addiction Consult Service: A Mixed-methods Study	28
A Plea From People Who Use Drugs to Clinicians: New Ways to Initiate Buprenorphine Are Urgently Needed in the Fentanyl Era	26
Assessment of Kratom Use Disorder and Withdrawal Among an Online Convenience Sample of US Adults	25
Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-analysis	22
Synergistic Effect of Ketamine and Buprenorphine Observed in the Treatment of Buprenorphine Precipitated Opioid Withdrawal in a Patient With Fentanyl Use	21
Trends in Hospitalizations for Serious Infections Among People With Opioid Use Disorder in Ontario, Canada	21
Emerging Characteristics of Isotonitazene-Involved Overdose Deaths: A Case-Control Study	20
The Use of Kratom (Mitragyna speciosa Korth.) Among People Who Co-use Heroin and Methamphetamine in Malaysia	20
Low-threshold Buprenorphine Treatment in a Syringe Services Program: Program Description and Outcomes	20
DEA Disconnect Leads to Buprenorphine Bottlenecks	20
Barriers to Care Experienced by Patients Who Inject Drugs During the COVID-19 Pandemic: A Qualitative Analysis	19
Fentanyl Absorption, Distribution, Metabolism, and Excretion: Narrative Review and Clinical Significance Related to Illicitly Manufactured Fentanyl	18
Adaptation of a System of Treatment for Substance Use Disorders During the COVID-19 Pandemic	18
Shifting Medication Treatment Practices in the COVID-19 Pandemic: A Statewide Survey of Pennsylvania Opioid Treatment Programs	18

Geriatric Conditions Among Middle-aged and Older Adults on Methadone Maintenance Treatment: A Pilot Study	18
Causes of Death in the 12 Months After Hospital Discharge Among Patients With Opioid Use Disorder	17
Evidence on Buprenorphine Dose Limits: A Review	16
Disparities in Documented Drug Use Disorders Between Transgender and Cisgender U.S. Veterans Health Administration Patients	16
Permanent Methadone Treatment Reform Needed to Combat the Opioid Crisis and Structural Racism	16
Thematic Analysis of Reddit Content About Buprenorphine-naloxone Using Manual Annotation and Natural Language Processing Techniques	16
Differential Gateways, Facilitators, and Barriers to Substance Use Disorder Treatment for Pregnant Women and Mothers: A Scoping Systematic Review	16
Alcohol Consumption During the First Year of the COVID-19 Pandemic in the United States: Results From a Nationally Representative Longitudinal Survey	16
Revisiting the X:BOT Naltrexone Clinical Trial Using a Comprehensive Survival Analysis	16
During the COVID-19 Pandemic, Opioid Overdose Deaths Revert to Previous Record Levels in Ohio	16
Polysubstance Overdose Deaths in the Fentanyl Era: A Latent Class Analysis	16
Healthcare Patterns of Pregnant Women and Children Affected by OUD in 9 State Medicaid Populations	15
Inpatient Opioid Use Disorder Treatment by Generalists is Associated With Linkage to Opioid Treatment Programs After Discharge	15
Potential Value of the Insights and Lived Experiences of Addiction Researchers With Addiction	15
Micro-dosing Intravenous Buprenorphine to Rapidly Transition From Full Opioid Agonists	15
Emergency Department-initiated Buprenorphine and Referral to Follow-up Addiction Care: A Program Description	15
Widespread Distribution of Xylazine Detected Throughout the United States in Healthcare Patient Samples	14
Assessing Stigma Towards Substance Use in Pregnancy: A Randomized Study Testing the Impact of Stigmatizing Language and Type of Opioid Use on Attitudes Toward Mothers With Opioid Use Disorder	14
A Case of Potential Pharmacokinetic Kratom-drug Interactions Resulting in Toxicity and Subsequent Treatment of Kratom Use Disorder With Buprenorphine/Naloxone	14
Reduction in Oregon's Medication Dosing Visits After the SARS-CoV-2 Relaxation of Restrictions on Take-home Medication	14
Virtual Twelve Step Meeting Attendance During the COVID-19 Period: A Study of Members of Narcotics Anonymous	14
Toward a Typology of Office-based Buprenorphine Treatment Laws: Themes From a Review of State Laws	14
Explaining Racial-ethnic Disparities in the Receipt of Medication for Opioid Use Disorder during Pregnancy	14
COVID-19 and Cannabidiol (CBD)	13
The Need for Multidisciplinary Hospital Teams for Injection Drug Use-related Infective Endocarditis	13
Perspectives of Patients Receiving Telemedicine Services for Opioid Use Disorder Treatment: A Qualitative Analysis of User Experiences	13
Treatment for Anxiety and Substance Use Disorders During the COVID-19 Pandemic: Challenges and Strategies	13
Recognition and Treatment of Wounds in Persons Using Xylazine: A Case Report From New Haven, Connecticut	12
Use of a Telemedicine Bridge Clinic to Engage Patients in Opioid Use Disorder Treatment	12
Cannabidiol Effect on Anxiety Symptoms and Stress Response in Individuals With Cocaine Use Disorder: Exploratory Results From a Randomized Controlled Trial	12
Discontinuing Methadone and Buprenorphine: A Review and Clinical Challenges	12
Improving Research on Racial Disparities in Access to Medications to Treat Opioid Use Disorders	11
Cannabis Legalization and Adolescent Use of Electronic Vapor Products, Cannabis, and Cigarettes	11
Xylazine-associated Wounds: Clinical Experience From a Low-barrier Wound Care Clinic in Philadelphia	11
Simultaneous Management of Alcohol Use Disorder and Liver Disease: A Systematic Review and Meta-analysis	11
Self-reported Xylazine Experiences: A Mixed-methods Study of Reddit Subscribers	11
Sexually Transmitted and Blood-borne Infections Among Patients Presenting to a Low-barrier Substance Use Disorder Medication Clinic	10
Pressure Necrosis Requiring Fasciotomy After Kratom Overdose	10
Civil Commitment for Substance Use Disorders: A National Survey of Addiction Medicine Physicians	10
In-hospital Substance Use Policies: An Opportunity to Advance Equity, Reduce Stigma, and Offer Evidence-based Addiction Care	10
ASAM Clinical Considerations: Buprenorphine Treatment of Opioid Use Disorder for Individuals Using High-potency Synthetic Opioids	10
Patient Characteristics Associated With Phone Versus Video Telemedicine Visits for Substance Use Treatment during COVID-19	9
An Integrated Care Model for Pregnant and Postpartum Individuals Receiving Medication for Opioid Use Disorder	9
The Impact of COVID-19 on Service Provision for Emergency Department Patients Post-Opioid Overdose: A Field Report	9
Injecting Opioid Use Disorder Treatment in Jails and Prisons: The Potential of Extended-release Buprenorphine in the Carceral Setting	9
Social Determinants of Mortality of COVID-19 and Opioid Overdose in American Rural and Urban Counties	9
Evaluation of the BEAT Meth Intervention for Emergency Department Patients with Methamphetamine Psychosis	9
Cannabis Use and Stroke: Does a Risk Exist?	9
Medication for Addiction Treatment and Postpartum Health Care Utilization Among Pregnant Persons With Opioid Use Disorder	9
Barriers and Facilitators to Buprenorphine Prescribing for Opioid Use Disorder in the Veterans Health Administration During COVID-19	9

Co-occurring Substance Use Disorders Identified Among Delivery Hospitalizations in the United States	9
Low-Threshold Buprenorphine via Community Partnerships and Telemedicine—Case Reports of Expanding Access to Addiction Treatment During COVID-19	9
Harnessing the Power of Social Media to Understand the Impact of COVID-19 on People Who Use Drugs During Lockdown and Social Distancing	9
Low Dose Buprenorphine Induction With Full Agonist Overlap in Hospitalized Patients With Opioid Use Disorder: A Retrospective Cohort Study	9
Rapid Overlap Initiation Protocol Using Low Dose Buprenorphine for Opioid Use Disorder Treatment in an Outpatient Setting: A Case Series	8
Substance Use and Utilization of Prenatal and Postpartum Care	8
A Proposal for Addiction and Infectious Diseases Specialist Collaboration to Improve Care for Patients With Opioid Use Disorder and Injection Drug Use-Associated Infective Endocarditis	8
Association Between Benzodiazepine and Opioid Prescription and Mortality Among Patients in a Large Healthcare System	8
Skin Necrosis Following Inadvertent Dermal Injection of Extended-release Buprenorphine	8
The Use of Once-monthly Injectable Buprenorphine for the Treatment of Opioid Use Disorder in Postpartum Women: A Case Series	8
Strategies for Transfer From Methadone to Buprenorphine for Treatment of Opioid Use Disorders and Associated Outcomes: A Systematic Review	8
Trends in Substance Use Disorder-related Admissions at a Safety-net Hospital, 2008 – 2020	8
False-positive Fentanyl Urine Detection After Initiation of Labetalol Treatment for Hypertension in Pregnancy: A Case Report	8
First-line Medications for the Outpatient Treatment of Alcohol Use Disorder: A Systematic Review of Perceived Barriers	8
Treatment Disruption and Childcare Responsibility as Risk Factors for Drug and Alcohol Use in Persons in Treatment for Substance Use Disorders During the COVID-19 Crisis	8
Precipitated Opioid Withdrawal Treated With Ketamine in a Hospitalized Patient: A Case Report	8
Anhedonia and Substance Use Disorders by Type, Severity, and With Mental Health Disorders	7
Initiation of Low-threshold Buprenorphine in Nontreatment Seeking Patients With Opioid Use Disorder Engaged in Hepatitis C Treatment	7
Utilization of Medications for Opioid Use Disorder Across US States: Relationship to Treatment Availability and Overdose Mortality	7
Opioid Use Behaviors Among People With Disability in the United States: An Analysis of the National Survey on Drug Use and Health	7
HIV Exposure Prophylaxis Delivery in a Low-barrier Substance Use Disorder Bridge Clinic during a Local HIV Outbreak at the Onset of the COVID-19 Pandemic	7
Understanding Contraceptive Needs of Women Who Inject Drugs in Orange County: A Qualitative Study	7
Pregnancy and the Opioid Crisis: Heightened Effects of COVID-19	7
Virtual Care in an Outpatient Subspecialty Substance Use Disorder Treatment Program	7
Pregnant Patients Using Opioids: Treatment Access Barriers in the Age of COVID-19	7
Prescribing the Buprenorphine Monoproduct for Adverse Effects of Buprenorphine-Naloxone	7
2021 Poster Abstracts	7
Factors Associated With Drug Overdoses During the COVID-19 Pandemic	7
Treating Opioid Use Disorder in Puerto Rico During the COVID-19 Pandemic: Providers’ Leadership Efforts in Unprecedented Times	6
“Nobody Knows How You’re Supposed to Interpret it:” End-user Perspectives on Prescription Drug Monitoring Program in Massachusetts	6
Preconception Substance Use and Risk of Unintended Pregnancy: Pregnancy Risk Assessment Monitoring System 2016–17	6
Anticipated Barriers to Sustained Engagement in Treatment With Medications for Opioid Use Disorder After Release From Incarceration	6
Successful Buprenorphine/Naloxone Low-dose Induction in Pregnancy: A Case Report	6
An Exploration of Young Adults With Opioid Use Disorder and How Their Perceptions of Family Members’ Beliefs Affects Medication Treatment	6
Commentary on Ajazi et al (2021) Re-analysis of the X:BOT Trial	6
Effectiveness of and Access to Medications for Opioid Use Disorder for Adolescents and Young Adults: A Scoping Review	6
Food Insecurity and Substance Use Among Young Adult College Students in the United States	6
Impact of Prenatal Cannabis Use Disorder on Perinatal Outcomes	6
Office-based Methadone Prescribing for Opioid Use Disorder: The Canadian Model	6
The Naloxone Component of Buprenorphine/Naloxone: Discouraging Misuse, but at What Cost?	6
Providing Low-barrier Addiction Treatment Via a Telemedicine Consultation Service During the COVID-19 Pandemic in Los Angeles, County: An Assessment 1 Year Later	6
Buprenorphine-naloxone versus Buprenorphine for Treatment of Opioid Use Disorder in Pregnancy	6
The Incidence and Disparities in Use of Stigmatizing Language in Clinical Notes for Patients With Substance Use Disorder	6
A Pilot Investigation of Nonpharmacological Pain Management Intervention Groups in Methadone Maintenance Treatment	6
Buprenorphine Initiation in the Era of High-Potency Synthetic Opioids: A Call for Community-Based Participatory Research to Help Learning Health Systems Provide Precision Medicine for Opioid Use Disor	6
Factors Associated With Increased Opioid Use During the COVID-19 Pandemic: A Prospective Study of Patients Enrolled in Opioid Agonist Treatment	6
Investigating Healthcare Provider Bias Toward Patients Who Use Drugs Using a Survey-based Implicit Association Test: Pilot Study	6
Statewide Availability of Buprenorphine/Naloxone in Acute Care Hospitals	6
Long-Term Effects of Increasing Buprenorphine Treatment Seeking, Duration, and Capacity on Opioid Overdose Fatalities: A Model-based Analysis	6
COVID-19 Social Distancing and Online Mutual Help Engagement for Alcohol Use Recovery	6
Opioid-related Emergency Department Visits During COVID-19 in a Large Health System	6
Adaptations to Opioid Use Disorder Care During the COVID-19 Pandemic: A National Survey of Prescribers	5
Addressing Methamphetamine Use in Primary Care: Provider Perspectives	5
Therapy Dose Mediates the Relationship Between Buprenorphine/Naloxone and Opioid Treatment Outcomes in Youth Receiving Medication for Opioid Use Disorder Treatment	5
Evidence of Designer Benzodiazepine Use in Routine Healthcare Urine Drug Specimens	5
Thirty-day Treatment Continuation After Audio-only Buprenorphine Telehealth Initiation	5
Recognizing and Reducing the Impact of Trauma of Hospitalization: Considerations for Persons Who Use Drugs	5
Feasibility of Emergency Department–based Fentanyl Test Strip Distribution	5
Longitudinal Associations Between Use of Tobacco and Cannabis Among People Who Smoke Cigarettes in Real-world Smoking Cessation Treatment	5
The Role of Primary Care in the Initiation of Opioid Use Disorder Treatment in Statewide Public and Private Insurance	5
Opioid Use Disorder Treatment in the Fentanyl Era	5
Enhancing Patient Choice: Using Self-administered Intranasal Naloxone for Novel Rapid Buprenorphine Initiation	5
Maternal Cannabis Use in the Perinatal Period: Data From the Pregnancy Risk Assessment Monitoring System Marijuana Supplement, 2016–2018	5
Discordance Between Self-reported and Biologically Tested Exposure to Fentanyl Among People at Risk of Opioid Overdose	5
A Case of Phenibut Directed Detoxification Leading to Toxicity During the COVID-19 Pandemic	5
Exercise Addiction Stability and Health Effects. A 6-Month Follow-up Postcompetition Study in Amateur Endurance Cyclists	5
The Relationship Between Reductions in WHO Risk Drinking Levels During Treatment and Subsequent Healthcare Costs for the ACTIVE Workgroup	5
Implementation of Telemedicine Delivery of Medications for Opioid Use Disorder in Pennsylvania Treatment Programs During COVID-19	5
Use of Injectable Opioid Agonist Therapy in a In-Patient Setting for a Pregnant Patient With Opioid Use Disorder: A Case Report	5
Responses to a “Typical” Morning Dose of Kratom in People Who Use Kratom Regularly: A Direct-Observation Study	5
Nudging Emergency Department-Initiated Addiction Treatment	5
Stigmatizing Terminology for Outcomes and Processes (STOP) in Alcohol Research: A Meta-epidemiologic Assessment of Language Used in Clinical Trial Publications	5
The Impact of a PDMP-EHR Data Integration Combined With Clinical Decision Support on Opioid and Benzodiazepine Prescribing Across Clinicians in a Metropolitan Area	5
Characterizing the Clinical use of a Novel Video-assisted Dosing Protocol With Secure Medication Dispensers to Reduce Barriers to Opioid Treatment	5
Current State of Perioperative Buprenorphine Management—A National Provider Survey	5
Challenges of Diagnosing and Managing Designer Benzodiazepine Dependence and Withdrawal: A Case Report	5
Take-Home Naloxone and the Need for a Publicly Funded Naloxone Supply	5
Under the Skin: The Relationship Between Subcutaneous Injection and Skin Infections Among People Who Inject Drugs	5
Extreme Binge Drinking During Adolescence: Associations With Subsequent Substance Use Disorders in American Indian and Mexican American Young Adults	5
Syringe Service Program Perspectives on Barriers, Readiness, and Programmatic Needs to Support Rollout of the COVID-19 Vaccine	4

Use of Electronic Health Record Data to Estimate the Probability of Alcohol Withdrawal Syndrome in a National Cohort of Hospitalized Veterans	4
Dispensing Methadone at Hospital Discharge: One Hospital's Approach to Implementing the “72-hour Rule” Change	4
Recovery Capital Correlates With Less Methamphetamine Use and Crime in the Community	4
Interventions Addressing Cannabis Use During Pregnancy: A Systematic Review	4
Initiation of Medications for Opioid Use Disorder Shortly Before Release From Prison to Promote Treatment Retention: Strong Evidence but Compromised Policy	4
International Classification of Diseases (ICD) Codes Fail to Accurately Identify Injection Drug Use Associated Endocarditis Cases	4
Opting into the Public List of DATA-Waivered Practitioners: Variations by Specialty, Treatment Capacity, and Practitioner Characteristics	4
Rapid Low-dose Buprenorphine Initiation for Hospitalized Patients With Opioid Use Disorder	4
Microdose Induction of Buprenorphine in a Patient Using Tianeptine	4
Defining Opioid-related Problems Using a Health Care Safety Net Institution’s Inpatient Electronic Health Records: Limitations of Diagnosis-based Definitions	4
Integration of Patient-reported Outcomes Assessment Into Routine Care for Patients Receiving Residential Treatment for Alcohol and/or Substance Use Disorder	4
Regular Kratom (Mitragyna speciosa Korth.) Use and Its Association With Endoplasmic Reticulum Stress Response	4
A Bridge to Nowhere: Resistance to the Possibility of Some Heavy Drinking During Recovery and the Potential Public Health Implications	4
A Low-threshold Comprehensive Shared Medical Appointment Program for Perinatal Substance Use in an Underserved Population	4
Rethinking Home-based Outpatient Parenteral Antibiotic Therapy for Persons Who Inject Drugs: An Opportunity for Change in the Time of COVID-19	4
COVID-19 Vaccination Status and Concerns Among People Who Use Drugs in Oregon	4
“Macrodosing” Sublingual Buprenorphine and Extended-release Buprenorphine in a Hospital Setting: 2 Case Reports	4
Supervised Tablet Injectable Opioid Agonist Therapy (TiOAT): A Strategy to Address Safer Supply for Individuals With an Opioid Use Disorder?	4
Involuntary Commitment for Substance Use: Addiction Care Professionals Must Reject Enabling Coercion and Patient Harm	4
Severe, Nondelirium Agitation as an Underreported Characteristic of Precipitated Fentanyl Withdrawal: A Case Report	4
Low Uptake of Secure Messaging Among Veterans With Experiences of Homelessness and Substance Use Disorders	4
What's in an “ASAM-based Assessment?” Variations in Assessment and Level of Care Determination in Systems Required to Use ASAM Patient Placement Criteria	4
Perception of Resource Allocations to Address the Opioid Epidemic	4
Synthetic Cathinone–Induced Myocarditis and Psychosis: A Case Report	4
Continued Posttrial Benefits of Buprenorphine Extended Release: RECOVER Study Findings	4
Barriers to Engagement in Opioid Use Disorder Treatment After Buprenorphine Induction	4
Retention and Overdose Risk among Patients Receiving Substance Use Disorder Treatment, Mental Health Care and Peer Recovery Support: A Longitudinal Analysis	4
48-hour Induction of Transdermal Buprenorphine to Sublingual Buprenorphine/Naloxone: The IPPAS Method	4
Low Threshold Telemedicine-based Opioid Treatment for Criminal Justice Involved Adults During the COVID-19 Pandemic: A Case Report	4
Clinical Presentations and Treatment of Phenibut Toxicity and Withdrawal: A Systematic Literature Review	4
Participant Experiences of a Quit Smoking Attempt Through Either Nicotine Replacement Therapy (NRT) Methods or the Use of an E-cigarette	4
A Mixed-methods Evaluation of an Addiction/Cardiology Pilot Clinic With Contingency Management for Patients With Stimulant-associated Cardiomyopathy	4
Provider Continuity in the Prescribing of Buprenorphine/Naloxone Within Medicare Part D	4
Outcomes in Subsequent Pregnancies of Individuals With Opioid Use Disorder Treated in Multidisciplinary Clinic in Prior Pregnancy	4
Patient Satisfaction With Standard Methadone and Flexible Buprenorphine/Naloxone Models of Care: Results From a Pragmatic Randomized Controlled Clinical Trial	4